A Closer Look at Allergan’s International Business
Allergan’s International segment reported a 13.4% YoY (year-over-year) rise in revenues to $858.5 million in 2Q17, compared with $757.0 million in 2Q16.
Allergan’s US General Medicines segment reported a 1.5% fall in revenues to $1.43 billion during 2Q17, compared to $1.45 billion in 2Q16.
Allergan’s US Specialized Therapeutics segment includes eye care, medical aesthetics, medical dermatology, and neuroscience and urology products.
Allergan’s US Specialized Therapeutics segment reported a ~15% rise in revenues to $1.7 billion in 2Q17, compared with $1.49 billion in 2Q16.
Allergan reported revenues of $4.01 billion for 2Q17—an 8.8% rise over 2Q16, driven by the strong performance of key brands in specialized therapeutics.
On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards.
Out of 37 analysts covering Visa (V), five or 13.51% have rated the stock a “hold.” “Buy” ratings have been given by 15 analysts’ (40.54%) and “strong buy” rating have been given by 17 analysts or 45.95%.
Wall Street analysts have given a one-year price target of $110.00 per share for Visa stock (V). The target represents an increase of 4.46% from the current stock price.
As of September 30, 2016, Visa (V) has reported a total asset balance of $64.03 billion. As of June 30, 2017, the company managed to report a total asset balance of $64.00 billion.
Visa (V) reported total operating expenses of $5.56 billion from fiscal 1Q16 to fiscal 3Q16 and $4.57 billion from fiscal 1Q17 to fiscal 3Q17, representing a substantial fall of 18%.
Visa (V) has reported net operating revenues amounting to $10.8 billion from fiscal 1Q16 to fiscal 3Q16 and $13.5 billion from fiscal 1Q17 to fiscal 3Q17, reflecting an increase of 25%.
Dentsply Sirona (XRAY) closed at $57.81 on September 21, 2017. In the past one month, XRAY stock has risen 9.5%.
On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.
Dentsply Sirona (XRAY) and Zephyr Sleep Technologies have entered into a strategic partnership for the treatment of OSA (obstructive sleep apnea).
According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”
As of September 20, 2017, AT&T (T) was the largest US telecom carrier by market capitalization.
Frontier (FTR) continues to invest in capital expenditures (or capex) to enhance its network.
As Frontier offered faster speeds and new offers, the company’s broadband net additions improved sequentially in the California, Texas, and Florida (or CTF) markets during 2Q17.
Frontier (FTR) believes that its video services could act as a growth driver in the near future.
During the Goldman Sachs Communacopia Conference on September 12, 2017, Perley McBride, Frontier’s chief financial officer, discussed the company’s full-year 2017 guidance.